
Sutro Biopharma
(NASDAQ) STRO
Sutro Biopharma Financials at a Glance
Market Cap
$497.61M
Revenue (TTM)
$99.61M
Net Income (TTM)
-$153.60M
EPS (TTM)
-$16.45
P/E Ratio
-1.83
Dividend
$0.00
Beta (Volatility)
1.32 (Average)
Dividend
$0.00
Beta (Volatility)
1.32 (Average)
Price
$30.06
Volume
2
Open
$29.29
Price
$30.06
Volume
2
Open
$29.29
Previous Close
$30.03
Daily Range
$29.29 - $31.79
52-Week Range
$6.74 - $43.85
Estimated Earnings Date
Aug 6, 2026
Dividend
$0.00
Beta (Volatility)
1.32 (Average)
Price
$30.06
Volume
2
Open
$29.29
Previous Close
$30.03
Daily Range
$29.29 - $31.79
52-Week Range
$6.74 - $43.85
Estimated Earnings Date
Aug 6, 2026
STRO News
STRO: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Sutro Biopharma
Industry
Biotechnology
Sector
Health CareEmployees
137
CEO
Jane Chung
Website
www.sutrobio.comHeadquarters
South San Francisco, CA 94080, US
STRO Financials
Key Financial Metrics (TTM)
Gross Margin
98.72%
Operating Margin
-115.53%
Net Income Margin
-154.21%
Return on Equity
192.77%
Return on Capital
N/A
Return on Assets
-63.48%
Earnings Yield
-54.64%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$497.61M
Shares Outstanding
16.57M
Volume
2
Avg. Volume
276.37K
Financials (TTM)
Gross Profit
$98.33M
Operating Income
-$115.08M
EBITDA
-$106.12M
Operating Cash Flow
-$151.61M
Capital Expenditure
-$532.00K
Free Cash Flow
-$152.14M
Cash & ST Invst.
$202.56M
Total Debt
$13.63M
Sutro Biopharma Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$14.52M
-16.5%
Gross Profit
$13.25M
-23.9%
Gross Margin
91.20%
N/A
Market Cap
$497.61M
N/A
Market Cap/Employee
$1.85M
N/A
Employees
269
N/A
Net Income
-$38.48M
+49.3%
EBITDA
-$27.75M
+39.1%
Quarterly Fundamentals
Total Cash
$202.56M
-18.6%
Total Debt
$13.63M
-36.3%
Accounts Receivable
$12.48M
-7.9%
Inventory
$0.00
N/A
Long Term Debt
$6.03M
-55.8%
Short Term Debt
$7.60M
-2.1%
Return on Assets
-63.48%
N/A
Return on Invested Capital
-67.23%
N/A
Free Cash Flow
-$42.27M
+38.8%
Operating Cash Flow
-$42.26M
+37.7%

